Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 6 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in a Cohort of Women with Antiphospholipid Syndrome. 25- Years Long-Term Observation
Dana Tegzova¹, Katerina Andelova², Iva Kucerova², Vera Vlasakova³, Stejskal Jan⁴, Putova Ivana⁵, Marta Olejarova⁶ and Ctibor Dostál⁷, ¹Clinical Department, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ²Institute of Mother and Child Care, Prague, Prague, Czech Republic, ³Dept.of Internal Medicine, City Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic, ⁴1st Medical Faculty, Dpt. of Pathology, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Dpt. of Immunology, Prague, Czech Republic, ⁶Clinical, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic
Background/Purpose: The goal of this long-term project was to investigate the course of pregnancy in patients with APS (primary or secondary with SLE) in 1993-2017,…
Abstract Number: 8 • 2017 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Leukocytes Demonstrate Increased Adhesive Potential: a Search for Novel Therapeutic Targets
Gautam Sule¹, William J. Kelley¹, Srilakshmi Yalavarthi¹, Alison Banka¹, Omolola Eniola-Adefeso¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Adhesion of leukocytes to the endothelium is an initiating event in the thrombosis inherent to antiphospholipid syndrome (APS). Over the years, a number of…
Abstract Number: 13 • 2017 ACR/ARHP Annual Meeting
Epidemiology of Antiphospholipid Syndrome: A Population-Based Study
Ali Duarte-Garcia¹, Michael Pham¹, Cynthia S. Crowson², Kevin Moder³, Rajiv Pruthi⁴ and Eric L. Matteson⁵, ¹Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, R, MN, ⁵Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: The epidemiology of definite antiphospholipid syndrome (APS) in the general population has not been described. A recent meta-analysis (Andreoli L, et al. Arth Care…
Abstract Number: 14 • 2017 ACR/ARHP Annual Meeting
Abnormalities in Th1, Th2 and Th17 Lymphoid Subpopulations in Long-Term Evolution Primary Antiphospholipid Syndrome
Gabriela Medina¹, Oscar I Florez-Durante², Laura Arcelia Montiel Cervantes³, Rubiraida Molina Aguilar², Elba Reyes Maldonado² and Luis J. Jara⁴, ¹Clinical Research Unit, Hospital de Especialidades Centro Medico La Raza,IMSS, Mexico City, Mexico, ²Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico, ³Hematology Laboratory, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ⁴Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico
Background/Purpose: Primary antiphospholipid antibody syndrome (PAPS) is characterized by recurrent thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). Lymphoid subpopulations and innate…
Abstract Number: 15 • 2017 ACR/ARHP Annual Meeting
Methodology and Systematic Review of the Literature for the Mcmaster RARE-Best Practice Clinical Practice Guideline on Diagnosis and Management of the Catastrophic Antiphospholipid Syndrome
Kimberly Legault¹, Christopher Hillis¹, Cindy Yeung¹, Elie Akl², Marc Carrier³, Ricard Cervera⁴, Mark Crowther¹, Francesco Dentali⁵, Doruk Erkan⁶, Gerard Espinosa⁷, Munther A Khamashta⁸, Joerg Meerpohl⁹, Karen Moffatt¹⁰, Sarah O'Brien¹¹, Vittorio Pengo¹², Jacob Rand¹³, Ignasi Rodriguez¹⁴, Lisa Thom¹⁵, Holger Schunemann¹ and Alfonso Iorio¹, ¹McMaster University, Hamilton, ON, Canada, ²American University of Beirut, Beirut, Lebanon, ³University of Ottawa, Ottawa, ON, Canada, ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Insubria University, Insubria, Italy, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁷Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁸Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ⁹University of Freiburg, Freiburg, Germany, ¹⁰Hamilton Health Sciences, Hamilton, ON, Canada, ¹¹Nationwide Children's, Columbus, OH, ¹²Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ¹³NY Presbyterian Hospital, New York, NY, ¹⁴Rheumatology, Hospital Clinica, Barcelona, Spain, ¹⁵None (patient representative), Oxford, United Kingdom
Background/Purpose: Catastrophic antiphospholipid syndrome (CAPS), a rare disease, is characterized by the rapid onset of widespread thrombosis associated with multi-organ failure in patients meeting the…
Abstract Number: 2086 • 2016 ACR/ARHP Annual Meeting
Hexagonal Phase Phospholipid Neutralization Assay Is the Most Sensitive but Least Specific Among Nine Tests for Detecting APS in SLE or Non-SLE Patients
Katalin Banki¹, Phillip Aleksiejuk², Jessica Patel² and Andras Perl³, ¹Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ²Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Department of Medicine, Upstate Medical University, Syracuse, NY
Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune, hypercoagulable state which may elicit thrombosis and pregnancy loss. Although several tests exist to guide diagnosis of…
Abstract Number: 2087 • 2016 ACR/ARHP Annual Meeting
A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome
Lucas L. van den Hoogen¹, Ruth D.E. Fritsch-Stork², Marjan A. Versnel³, Ronald H.W.M. Derksen⁴, Joel A.G. van Roon^5,6 and Timothy R.D.J. Radstake^5,6, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Departments of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands
Background/Purpose: In several autoimmune diseases, most notably in systemic lupus erythematosus (SLE), a type I interferon (IFN) signature has been described. This signature is thought…
Abstract Number: 2090 • 2016 ACR/ARHP Annual Meeting
Investigating the Genetic Variations of Antiphospholipid Syndrome By High-Throughput Exome Sequencing
Sung-Hoon Park¹, Chan Uk Lee¹, Ji Na Kim², Ji-Won Kim¹, Hwajeong Lee², Seong-Kyu Kim² and Jung-Yoon Choe¹, ¹Medicine, Catholic university of Daegu School of medicine, Daegu, Korea, The Republic of, ²Catholic university of Daegu School of medicine, Daegu, Korea, The Republic of
Background/Purpose: The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies in serum together with clinical manifestations such as thrombosis,…
Abstract Number: 2092 • 2016 ACR/ARHP Annual Meeting
Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Is Elevated in Patients with Thrombotic Primary Antiphospholipid Syndrome.
Yair Molad^1,2, Yonatan Edel^3,4, Yael Pri-Paz Basson⁵, Elisheva Pokroy-Shapira⁶, Shirly Oren⁵, Ariela Dortort⁵ and Vitaly Kliminski^4,7, ¹Rheumatology Unit, Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ²Laboratory of Inflammation Research, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ³Department of Medicine C, Beilinson Hospital, Rabib Medical Center, Petach Tikva, Israel, ⁴Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, ⁶Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ⁷Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel
Background/Purpose : Primary antiphospholipid syndrome (PAPS) is characterized by thrombotic and/or obstetrical morbidity in the presence of persistent antiphospholipid antibodies (APLA) and in the absence…
Abstract Number: 2094 • 2016 ACR/ARHP Annual Meeting
Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
Hiroyuki Nakamura¹, Kenji Oku², Ryo Hisada², Kazumasa Ohmura², Masaru Kato², Toshiyuki Bohgaki², Olga Amengual², Tetsuya Horita², Shinsuke Yasuda² and Tatsuya Atsumi², ¹Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Complement activation is proposed as one of the major thrombophilic mechanisms in antiphospholipid syndrome (APS). Among three complement pathways (classical, alternative and lectin), activation…
Abstract Number: 2095 • 2016 ACR/ARHP Annual Meeting
Autoantibodies Against High Density Lipoprotein-Associated Proteins Are Related to Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid Syndrome
Kenji Oku¹, Uhei Shibata², Joana Batuca³, Olga Amengual⁴, Michihiro Kono², Hiroyuki Nakamura⁵, Ryo Hisada¹, Kazumasa Ohmura¹, Masaru Kato², Toshiyuki Bohgaki¹, Shinsuke Yasuda¹, Jose Delgado Alves^3,6 and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³CEDOC/NOVA Medical School, Lisbon, Portugal, ⁴Hokkaido University,Medicine II, Sapporo, Japan, ⁵Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁶Fernando Fonseca Hospital, Amadora, Portugal
Background/Purpose: Oxidized low-density lipoprotein (oxLDL), a key molecule in atherogenesis, serves as the source of anionic charged particles that bind to beta2glycoprotein I (Β2GPI) and…
Abstract Number: 77 • 2016 ACR/ARHP Annual Meeting
Integrated Analysis of Microrna and mRNA Expression Profiles Related to Cardiovascular Disease in Monocytes from Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome Patients
Carlos Perez-Sanchez¹, Maria Ángeles Aguirre Zamorano¹, Patricia Ruiz-Limon², Nuria Barbarroja¹, Yolanda Jiménez-Gómez¹, Maria Carmen Abalos-Aguilera², Ivan Arias de la Rosa², María Galindo³, Eduardo Collantes-Estévez¹, Maria Jose Cuadrado⁴ and Chary Lopez-Pedrera¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁴St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: The interplay between miRNAs and their mRNA targets might constitute an important mechanism in the regulation of the proatherothrombotic status of SLE and APS…
Abstract Number: 2099 • 2016 ACR/ARHP Annual Meeting
Micrornas As Potential Modulators of Atherothrombosis in Antiphospholipid Syndrome
Patricia Ruiz-Limon¹, Maria Ángeles Aguirre Zamorano², Nuria Barbarroja², Yolanda Jiménez-Gómez², IVÁN ARIAS DE LA ROSA², Eduardo Collantes-Estévez², Pedro Segui², Francisco Velasco³, Rocio Gonzalez-Conejero⁴, Raul Teruel⁴, Constantino Martinez⁴, Maria Jose Cuadrado⁵, Carlos Perez-Sanchez² and Chary Lopez-Pedrera², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Hematology, IMIBIC-Reina Sofia Hospital, Hematology Unit, Cordoba, Spain, ⁴Regional Centre for Blood Donation, University of Murcia, Murcia, Spain, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: 1) To identify and characterize microRNAs linked to thrombosis and atherosclerosis development in APS; 2) To assess the effects of antiphospholipid antibodies in that…
Abstract Number: 920 • 2016 ACR/ARHP Annual Meeting
Autoantigen-Specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome
William Ruff¹, Carina Dehner², Alex Roth¹, Silvio M. Vieira¹, Cassyanne L. Aguiar^3,4, Andrew Goodman⁵, Doruk Erkan⁶ and Martin Kriegel¹, ¹Immunobiology, Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, new haven, CT, ³Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Cohen Children's Medical Center of New York/ Hofstra Northwell School of Medicine, Pediatric Rheumatology, New York, NY, ⁵Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Autoantigen-specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome William Ruff1, Carina Dehner1, Alex Roth1, Silvio M. Vieira1, Cassyanne L.…
Abstract Number: 2875 • 2016 ACR/ARHP Annual Meeting
Depressed Serum IgM Levels in SLE Are Restricted to Defined Subgroups
Caroline Grönwall¹, Uta Hardt¹, Iva Gunnarsson², Gregg J. Silverman³ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Department of Medicine, Unit of Rheumatology, Stockholm, Sweden, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Natural IgM autoantibodies have been proposed to have protective properties, and decreased levels of IgM to phosphorylcholine (PC) in SLE are associated with higher…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].